Furthermore, we evaluated the prognostic value of SHCBP1 in OS, showing that high SHCBP1 expression (H-score ≥ 70) correlates with a shorter OS time in cancer patients who received trastuzumab-based therapy (Fig. 2j). The gene discussed is SHCBP1; the disease is cancer.